<DOC>
	<DOCNO>NCT02999295</DOCNO>
	<brief_summary>The main purpose study evaluate safety efficacy combination therapy ramucirumab nivolumab participant advance recurrent unresectable gastric GEJ cancer .</brief_summary>
	<brief_title>A Phase 1/2 Study Ramucirumab Plus Nivolumab Participants With Gastric GEJ Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advanced recurrent unresectable gastric GEJ cancer Histologically confirm adenocarcinoma ( papillary adenocarcinoma , tubular adenocarcinoma poorly differentiate adenocarcinoma ) , signetring cell carcinoma , mucinous adenocarcinoma hepatoid adnocarcinoma Patients normal oral intake Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients measurable target lesion Patients refractory intolerant pretreatment pyrimidine fluoride anticancer agent platinumbased anticancer agent Patients adequate organ function Patients pretreatment history include ramucirumab , nivolumab therapy target control T cell Patients write informed consent Patients double cancer Patients infection require systemic therapy Known central vervous system ( CNS ) metastasis Patients history pneumonitis pulmonary fibrosis Patients history serious anaphylaxis induce antibody preparation Patients know active autoimmune disease history chronic recurrent autoimmune disease Female pregnant , lactate suspected pregnancy Patients psychosis dementia interfere obtain informed consent appropriately</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>